Kiniksa Pharmaceuticals, Ltd. - (KNSA) Social Stream
KINIKSA PHARMACEUTICALS LTD (KNSA) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering KNSA.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-28 | 3 | $37 | $26 | $30 | $18.31 | 63.84% |
| 2021-12-29 | 3 | $34 | $25.91 | $28.97 | $18.31 | 58.22% |
| 2022-02-22 | 3 | $34 | $27 | $29.666 | $18.31 | 62.02% |
| 2022-05-03 | 3 | $28 | $24 | $25.666 | $18.31 | 40.17% |
| 2022-08-03 | 3 | $28 | $22 | $25 | $18.31 | 36.54% |
| 2022-10-31 | 3 | $28 | $19 | $24 | $18.31 | 31.08% |
| 2023-02-08 | 3 | $28 | $19 | $24.333 | $18.31 | 32.89% |
| 2023-02-28 | 2 | $28 | $19 | $24.333 | $18.31 | 32.89% |
| 2023-03-03 | 2 | $28 | $19 | $22.333 | $18.31 | 21.97% |
| 2023-05-02 | 3 | $28 | $20 | $22.666 | $18.31 | 23.79% |
| 2023-07-25 | 3 | $28 | $20 | $23 | $18.31 | 25.61% |
| 2023-07-26 | 4 | $32 | $20 | $25.75 | $18.31 | 40.63% |
| 2023-10-31 | 4 | $32 | $23 | $26.75 | $18.31 | 46.1% |
| 2023-11-22 | 4 | $32 | $23 | $26.5 | $18.31 | 44.73% |
The Trend in the Analyst Price Target
Over the past 29 months, KNSA's average price target has gone down $5.5.
KNSA reports an average of 65.32% for its upside potential over the past 43 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-08 | 2 | 28 | 19 | 24.333 | 13.77 | 76.71% |
| 2023-03-03 | 3 | 28 | 19 | 22.333 | 12.28 | 81.86% |
| 2023-05-09 | 3 | 28 | 20 | 23.000 | 13.76 | 67.15% |
| 2023-08-09 | 4 | 32 | 23 | 26.750 | 17.48 | 53.03% |
| 2023-11-22 | 4 | 32 | 23 | 26.500 | 15.79 | 67.83% |
KNSA Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 4 | 0 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
KNSA's average broker recommendation rating improved by 0 over the prior 15 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for KNSA as an investment opportunity.
- In the context of all US stocks, KINIKSA PHARMACEUTICALS LTD's number of analysts covering the stock is greater than 132.9% of them.
- KNSA has a lower variance in analysts' estimates than -210.84% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, KINIKSA PHARMACEUTICALS LTD's upside potential (average analyst target price relative to current price) is higher than 467.66% of them.
- In terms of how KINIKSA PHARMACEUTICALS LTD fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 1040.48% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to KINIKSA PHARMACEUTICALS LTD are EOLS, OPTN, and SPRO.
View All Top Stocks by Price Target
What is the outlook for KNSA? Use POWR Ratings for clearer insight into price direction.